One tablet contains Allopurinol 100 mg or 300 mg.
PHARMACOLOGY: XANDASE inhibits the enzyme xanthine oxidase which catalyzes the oxidation of hypoxanthine to xanthine and of xanthine to uric acid. XANDASE lowers the serum uric acid level and eliminates uric acid deposits in the tissues. In contrast to uricosuric agents, XANDASE does not lead to a constantly increased elimination of uric acid via kidneys. There is no risk of crystalluria and formation of urinary stones.
Hyperuricaemia and chronic gout (both of which are on the increase). Not infrequently, the picture presented by gout is that of chronic polyarthritis.
Hyperuricaemia (above 6 mg% uric acid) may also be caused by diseases associated with increased nucleic acid catabolism, e.g. acute and chronic leukemia, polycythemia vera and psoriasis, as radio and chemotherapy of neoplasms and leukoses.
Initial dose up to 600 mg daily. This dosage permits the reduction of increased uric acid to normal levels within approximately 1 -3 weeks. The average dose 1 tablet daily.
Maintenance dose of ½-1 tablet daily, or as prescribed by physician.
Pregnancy and lactation period.
Often there is rapid improvement in the general condition of patients. Isolated cases respond to the treatment with pruritus and skin eruptions (urticaria), rise in temperature, eosinophilia and leukopenia. In these cases medication with XANDASE must be stopped.
M04AA01 - allopurinol ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.
Xandase tab 100 mg
50 × 10's
Xandase tab 300 mg
50 × 10's